PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Phaseolus vulgaris, commonly known as the common or kidney bean, is a globally cultivated legume serving as a significant source of dietary protein and calories [PMID:39459901, PMID:33282144]. Certain extracts are utilized as nutraceuticals for weight management via the inhibition of alpha-amylase [PMID:38830962, PMID:35485365].
Background
Phaseolus vulgaris is a legume indigenous to the Americas and is now cultivated on all continents [PMID:32314065]. It is a major crop used for human nutrition, particularly as a protein source in developing countries [PMID:39459901, PMID:35540177].
Active compounds
The herb contains proteins, carbohydrates, dietary fiber, and bioactive compounds such as anthocyanins, polyphenols, and flavonoids (e.g., quercetin), particularly in black bean varieties [PMID:37999428, PMID:28817105]. It also contains antinutrients including saponins, tannins, phytic acid, gossypol, and lectins [PMID:37999428].
Mechanism of action
Protein-based alpha-amylase inhibitors (α-AIs) in Phaseolus vulgaris reduce the activity of alpha-amylase through protein-protein interaction, which decreases the absorption rate of complex carbohydrates and reduces calorie intake [PMID:35485365, PMID:38830962].
Clinical evidence
Evidence BOverweight and moderate obesity
A proprietary aqueous extract (Phase 2 WKBE) significantly reduced body weight, fat mass, BMI, and waist and hip circumference in a dose-dependent manner over 12 weeks [PMID:38830962].
Evidence CObesity and metabolic health
Clinical and preclinical evidence suggests potential for weight regulation, suppression of starch digestion, attenuation of postprandial glycemia, and hypolipidemic effects [PMID:41300098].
Safety & adverse effects
Toxicity can be caused by lectins, saponins, phytates, and protease inhibitors, or through allergenicity induced by allergenic proteins [PMID:23410632]. Consumption may also lead to digestive system ailments and flatulence due to antinutrient content and oligosaccharides [PMID:37999428, PMID:32851056].
Dosage & administration
In one clinical trial, doses of 700 mg or 1000 mg of a proprietary aqueous extract were administered three times a day, 30 minutes before meals, for 12 weeks [PMID:38830962]. No PubMed data available. Consult a healthcare provider.
Evidence summary
Evidence for weight loss is supported by one randomized controlled trial (Level B) and narrative reviews (Level C). Safety data regarding toxicity and antinutrients are provided in review formats (Level C).
PubMed sources
- 1.PMID: 38830962 (2024) — Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial. · Scientific reports
- 2.PMID: 39459901 (2024) — Interactions between Common Bean Viruses and Their Whitefly Vector. · Viruses
- 3.PMID: 33282144 (2017) — Viruses infecting common bean (Phaseolus vulgaris L.) in Tanzania: A review on molecular characterization, detection and disease management options. · African journal of agricultural research
- 4.PMID: 32314065 (2020) — The promiscuity of Phaseolus vulgaris L. (common bean) for nodulation with rhizobia: a review. · World journal of microbiology & biotechnology
- 5.PMID: 35485365 (2022) — Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.